Communiqués BeyondSpring Inc.

Actions

BYSI

KYG108301006

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
2,42 ^USD	+7,56 %		+4,31 %	+168,89 %

21/05	Les plus fortes baisses du prémarché	MT
15/05	Transcript : BeyondSpring Inc. - Special Call

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BeyondSpring : Securities Purchase Agreement Form 6 K	12/06	PU
BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics	16/05	AQ
BEYONDSPRING TO HOST VIRTUAL R&D DAY TO DISCUSS NEW PLINABULIN DEVELOPMENT STRATEGY FOR CANCER AND UPDATES FOR SEED THERAPEUTICS	06/05	AQ
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics	03/05	AQ
BeyondSpring Files 2023 Annual Report on Form 20-F	29/04	AQ
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results	29/04	AQ
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer	25/03	AQ
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements	26/02	AQ
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K	10/01	AQ
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements	18/12	AQ
BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors	07/11	AQ
BEYONDSPRING AND PROFESSOR K. EISENMANN OF THE UNIVERSITY OF TOLEDO COLLEGE OF MEDICINE PRESENT POSTER HIGHLIGHTING PLINABULIN'S ANTI-CANCER EFFICACY IN PRIMARY AND RECURRENT GLIOBLASTOMA PATIENT DERIVED INVASIVE NEUROSPHERE MODELS	01/11	AQ
BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models	31/10/23	AQ
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement	30/10/23	AQ
SEED THERAPEUTICS DISCLOSES NOVEL MOLECULAR GLUE IND CANDIDATE FOR CANCER AT 'TARGETED PROTEIN DEGRADATION THINK TANK' SYMPOSIUM	27/10/23	AQ
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium	26/10/23	AQ
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors	23/10/23	AQ
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements	04/10/23	AQ
BEYONDSPRING AND LEADING CANCER CENTER TO PRESENT POSTER AT SITC'S 38TH ANNUAL MEETING	28/09/23	AQ
BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting	27/09/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués BeyondSpring Inc.

Actions

BYSI

KYG108301006

Communiqués

Filtres